Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"This new edition of 'Fast Facts: Heart Failure' starts with the definitions of HF (different types of HF require different treatments), then provides the latest thinking on mechanisms and clinical stages, underlying causes and the assessment and management of comorbidities. This is followed by simple diagnostic criteria and a comprehensive overview of investigations. The management chapters focus on the importance of self-care education and healthy lifestyle choices, together with the latest recommendations for pharmacological treatment, device therapy and cardiac surgery from international guidelines. The final chapter on developments is an indication of the ongoing innovation in this rapidly moving field."--

Blood physiology. Circulatory physiology --- Heart failure. --- Heart Failure --- Heart Failure.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Accounting for more than 40% of all heart failure problems, diastolic heart failure is a complex and often difficult diagnosis with rapidly evolving diagnostic management protocols. Diastology: Clinical Approach to Heart Failure with Preserved Ejection Fraction, 2nd Edition, brings you up to date and equips you to successfully diagnose and manage even the most challenging incidences of diastolic heart failure and their comorbidities. It incorporates the latest guidelines for the diagnostic evaluation of the patient with suspected or known diastolic dysfunction, provides a comprehensive review of clinical conditions associated with heart failure with preserved ejection fraction, and describes the complementary role of imaging modalities and novel therapeutic approaches"--Publisher's description.

Congestive heart failure. --- Heart --- Left ventricle --- Pathophysiology.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

La cardiomyopathie hypertrophique correspond à la cardiopathie la plus prévalente chez le chat, incitant les vétérinaires à accorder une importance particulière à sa gestion thérapeutique. Pourtant, une étude réalisée il y’a dix ans soulignait un déficit de littérature concernant l’approche médicale de cette pathologie, imposant aux vétérinaires de réaliser leur prise de décision pharmacothérapeutique sur base d’effets théoriques probablement bénéfiques, de leurs expériences personnelles favorables ou de simples transpositions d’effets bénéfiques observés chez l’homme ou chez le chien. Le but de ce travail est de dresser un nouvel état des lieux, dix ans plus tard, des avancées de la communauté scientifique concernant la prise en charge de cette pathologie très fréquente dans l’espèce féline.
Pour cela, nous commencerons par rappeler brièvement la pathophysiologie de cette maladie de façon à mettre en lumière les objectifs thérapeutiques et ainsi les familles pharmacologiques pouvant théoriquement être envisagées pour répondre à ceux-ci. Par la suite, nous passerons en revue la bibliographie relative à chacune de ces familles, en abordant pour chacune leur impact sur l’amélioration de la durée de vie et de la qualité de vie, puis nous soulèverons les questions relatives aux aspects pratiques de leur utilisation (possibilités d’optimisation de la compliance des propriétaires par le biais d’une adaptation de la posologie ou de la forme galénique). Enfin, nous conclurons en résumant les données disponibles au sein de la littérature et en proposant un schéma global de gestion thérapeutique pour chacun des stades de cette pathologie, incluant les aspects théoriques, bibliographiques et pratiques permettant d’optimiser la durée de vie et la qualité de vie des chats atteints de cardiomyopathie hypertrophique féline primaire. Hypertrophic cardiomyopathy is the most prevalent cardiac disease in cats, prompting veterinarians to take a close look at its therapeutic management. A study carried out ten years ago revealed however an important lack of information in the scientific literature concerning the medical approach of this pathology. This deficiency left veterinarians to rely solely on the supposedly positive effects of certain medicines, personal experience or extrapolations from human or dog therapy to make their pharmacotherapeutic decision when dealing with hypertrophic cardiomyopathy in cats. In this paper, we draw up the current state of play, ten years later, on the advances of the scientific community regarding the treatment of this frequent disease in feline species.
To achieve this, we will begin by briefly recalling the pathophysiology of this disease to highlight the therapeutic goals and pharmacological families that could be theoretically efficient in the case of hypertrophic cardiomyopathy. We will then make a review of the existing bibliography for each of these families by addressing their impact on the improvement of lifespan and quality of life, and by raising questions about the practicalities of their use (opportunities for optimizing the owners’ compliance through an adaptation of the dosage or the galenic formulation). Finally, we will conclude by summarizing the available data in the literature and we will suggest a comprehensive therapeutic management scheme for each stage of this pathology, including the theoretical, bibliographic and practical aspects allowing for the optimization of the lifespan and quality of life of cats with primary feline hypertrophic cardiomyopathy.

cardiomyopathie --- hypertrophique --- chat --- décompensation --- hypertrophic --- cardiomyopathy --- cat --- heart failure --- Sciences du vivant > Médecine vétérinaire & santé animale

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Dilated cardiomyopathy (DCM) is a particular phenotype of non-ischemic systolic heart failure, frequently recognizing a genetic background and affecting relatively young patients with few comorbidities. Nowadays, long-term survival of DCM patients has been markedly improved due to an early diagnosis and uninterrupted and tailored follow-up under constant optimal medical and non-pharmacological evidence-based treatments. Nevertheless, DCM is still one of the most common causes of heart transplantation in the western world. Clinical management requires an integrated and systematic use of diagnostic tools and a deeper investigation of the basic mechanisms underlying the disease. However, several emerging issues remain debated. Specifically, the genotype–phenotype correlation, the role of advanced imaging techniques and genetic testing, the lack of appropriate risk stratification models, the need for a multiparametric and multidisciplinary approach for device implantation, and a continuous reclassification of the disease during follow-up remain challenging issues in clinical practice. Therefore, the aim of this Special Issue is to shed the light on the most recent advancements in characterization and clinical management of DCM in order to unveil the conundrum of this particular disease.

Medicine --- SCN5A --- cardiac sodium channel --- cardiac channelopathy --- dilated cardiomyopathy --- precision medicine --- arrhythmias --- atrial fibrillation --- cardiomyopathy --- heart failure --- supraventricular arrhythmia --- systolic dysfunction --- tachycardiomyopathy --- ventricular arrhythmia --- left atrial strain --- cardiac resynchronization therapy --- muscular dystrophy --- calcium --- heart --- gene therapy --- phospholamban --- Serca2a --- mdx --- oxidative stress --- membrane stabilization --- left ventricular noncompaction --- congenital heart disease --- congestive heart failure --- non-ischemic cardiomyopathy --- genetics --- desmin --- mitochondrial dysfunction --- myopathy --- whole exome sequencing --- laminopathy --- LMNA --- biomarkers --- troponin T --- NT-proBNP --- malignant ventricular arrhythmia --- arrhythmic risk stratification --- DNA methylation --- alternative splicing --- epigenetics --- nonischemic dilated cardiomyopathy --- cardiac magnetic resonance imaging --- late gadolinium enhancement --- long axis strain --- left ventricle sphericity index --- major adverse cardiovascular events --- sex differences --- left ventricular reverse remodelling --- long-term outcomes --- left ventricle non-compaction cardiomyopathy --- cardiac magnetic resonance --- titin --- RNA binding motif protein 20 (RBM20) --- sarcomere --- diastolic dysfunction --- phosphorylation --- non-sense mRNA decay --- mammalian target of rapamycin (mTOR) complex-1 --- duchenne muscular distrophy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

With a mean worldwide prevalence of 13%, chronic kidney disease imposes a massive health burden on our society. In addition to reduced kidney function, patients with chronic kidney disease increasingly suffer from cardiovascular diseases affecting the heart and vasculature. Cardiovascular diseases account for around half of the deaths of patients with advanced chronic kidney disease. However, therapeutic options are highly insufficient. The pathological mechanisms that underlie increased cardiovascular risk in patients with chronic kidney disease remain largely unknown. This Special Issue provides insights into comorbidities in CKD patients, mainly focused on increased cardiovascular risk, and summarizes current knowledge of underlying pathophysiological mechanisms.

Medicine --- arterial stiffness --- carotid–femoral pulse wave velocity --- hemodialysis --- p-cresyl sulfate --- uremic toxins --- arterial calcification --- lipid metabolism --- inflammation --- coagulation --- endothelial dysfunction --- epigenetics --- chronic kidney disease --- uremic cardiopathy --- left ventricular hypertrophy --- phosphate --- PTH --- FGF23 --- klotho --- sclerostin --- chronodisruption --- chronodisruptor --- circadian rhythm --- internal clock --- uremia --- uremic cardiomyopathy --- organ crosstalk --- cardiorenal syndrome --- left-ventricular hypertrophy --- heart failure --- cardiac fibrosis --- cardiovascular disease --- vascular calcification --- experimental rodent models --- FGFG23 --- Klotho --- Wnt/β-catenin --- CKD --- parathyroid hormone --- secondary hyperparathyroidism --- uremic toxin --- ageing --- end-stage kidney disease --- premature ageing --- senescence --- bone --- gut --- cardiovascular --- CKD–MBD --- comorbidity --- fibrosis --- calcification